GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Online-Ressource
    Online-Ressource
    Naksh Solutions ; 2023
    In:  International Journal of Advanced Research in Science, Communication and Technology
    In: International Journal of Advanced Research in Science, Communication and Technology, Naksh Solutions
    Kurzfassung: The field of regulatory affairs (RA) serves as a link between the global pharmaceutical sector and regulators. It was created in response to governments’ desire to safeguard the public’s health by regulating the efficacy and safety of pharmaceuticals, veterinary drugs, medical equipment, pesticides, agricultural chemicals, cosmetics, and other goods. Companies that are in charge of the development, manufacture, testing, and sale of these products aim to guarantee that they deliver safe and efficient goods for the welfare of the general public. Different registration criteria for pharmaceutical products are covered by pharmaceutical drug regulatory affairs. As a result of the demand for superior quality medicine that includes safety and efficacy in the areas of not only pharmacy but also veterinary medicine, medical devices, insecticides, pesticides, agrochemicals, cosmetic, and supplementary medicine, a new profession called pharmacy was created. Additionally, it created a connection between the pharmaceutical corporation and the regulating bodies. Maintaining the appropriateness and accuracy of the product information is another duty assigned to it. And its primary responsibility is to serve as a point of contact for regulatory agencies, providing expertise and regulatory intelligence in translating regulatory requirements into realistic, workable plans, and advising the company on regulatory aspects and the regulatory environment that would affect their proposed projects..
    Materialart: Online-Ressource
    ISSN: 2581-9429
    Sprache: Englisch
    Verlag: Naksh Solutions
    Publikationsdatum: 2023
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Emerald ; 1987
    In:  International Journal of Quality & Reliability Management Vol. 4, No. 4 ( 1987-4-1), p. 61-72
    In: International Journal of Quality & Reliability Management, Emerald, Vol. 4, No. 4 ( 1987-4-1), p. 61-72
    Kurzfassung: Companies in the health field supplying drugs to government hospitals and medical services need to have accurate information on the relevant regulatory standards. This article describes a regulatory affairs and quality assurance programme instituted and operated by a major multinational drug manufacturer and supplier, referring to the appropriate British standards.
    Materialart: Online-Ressource
    ISSN: 0265-671X
    Sprache: Englisch
    Verlag: Emerald
    Publikationsdatum: 1987
    ZDB Id: 1466792-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Online-Ressource
    Online-Ressource
    Oxford University Press (OUP) ; 2020
    In:  Journal of AOAC INTERNATIONAL Vol. 103, No. 3 ( 2020-06-01), p. 705-709
    In: Journal of AOAC INTERNATIONAL, Oxford University Press (OUP), Vol. 103, No. 3 ( 2020-06-01), p. 705-709
    Kurzfassung: The U.S. Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA) oversees FDA field laboratories, monitoring the occurrence and levels of toxic mycotoxins in domestic and imported human and animal food products that have the potential to impact human and animal health when consumed. The mycotoxins being routinely monitored in human and animal foods and feeds by the Agency include aflatoxins (B1, B2, G1, G2, and M1), fumonisins (FB1, FB2, and FB3), deoxynivalenol, ochratoxin A, patulin, and zearalenone. There has been an ongoing expansion of the Sample Collection Operation Planning Effort (SCOPE) for the mycotoxin program to monitor more mycotoxins in a wider variety of food and feed matrices. To meet this pressing need, we are in the process of modernizing and harmonizing the FDA/ORA mycotoxin program in the field laboratories using approaches such as adopting new analytical technologies/methods to further advance the service. This short perspective gives an overview of the FDA mycotoxin program in the field laboratories and the current program status, discusses the need to advance the program, strategies for modernization and harmonization by implementing liquid chromatography-mass spectrometry technologies for multi-mycotoxin analysis, benefits of doing this, and challenges in taking this new approach. Perspectives on finding solutions to tackle challenges and addressing emerging issues are also discussed.
    Materialart: Online-Ressource
    ISSN: 1060-3271 , 1944-7922
    Sprache: Englisch
    Verlag: Oxford University Press (OUP)
    Publikationsdatum: 2020
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    Online-Ressource
    Online-Ressource
    Naksh Solutions ; 2022
    In:  International Journal of Advanced Research in Science, Communication and Technology
    In: International Journal of Advanced Research in Science, Communication and Technology, Naksh Solutions
    Kurzfassung: The regulatory bodies are being established in various pharmaceutical industries across the globe which plays a vital role to meet the requirements of legal procedures related to drug development process in a country. The pharmaceutical industry is considered as the most highly regulated industries worldwide. The regulatory body ensures compliances in various legal and regulatory aspects of a drug. Countries possess their own regulatory authority, which is responsible for enforcing the rules and regulations and issue the guidelines to regulate drug development process, licensing, registration, manufacturing, marketing, labeling and the product life cycle of pharmaceutical products. In an ever-changing regulatory environment, the role of regulatory affairs personnel is essential to ensure compliance with legislation in all regions in which a company wishes to distribute its drug. This article describes the development of the drugs as it is a cumbersome process which includes several months of time, volunteers, and a huge finical investment majorly through the funding process, so it is strictly regulated as per the norms and regulations as given by those individual countries to carry out the drug development which was generally governed by the Drug Regulatory Affairs Personals.
    Materialart: Online-Ressource
    ISSN: 2581-9429
    Sprache: Englisch
    Verlag: Naksh Solutions
    Publikationsdatum: 2022
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 5
    Online-Ressource
    Online-Ressource
    Oxford University Press (OUP) ; 2019
    In:  Journal of AOAC INTERNATIONAL Vol. 102, No. 4 ( 2019-07-01), p. 993-1002
    In: Journal of AOAC INTERNATIONAL, Oxford University Press (OUP), Vol. 102, No. 4 ( 2019-07-01), p. 993-1002
    Kurzfassung: Background: Regulatory affairs play a crucial role in the pharmaceutical industry and are incorporated in all stages of drug development. Objective: Approval criteria practices were developed as a resolution of the government’s desire to create policies to protect public health by controlling the safety and efficacy of merchandise in areas including pharmaceuticals, complementary color medicines, veterinary medicines, medical devices, and even food products and cosmetics. Method: Herbal health products are in practices in all parts of the world under either their legal system’s or expert council’s or agencies’ guides. They include botanicals, health supplements, health foods, complimentary medicines, traditional medicines or following pathies like Ayurveda, Yoga, Unani, Siddha, and Homeopathy. The requisite parameters for registration or recognition of products by various major global regulatory agencies were reviewed, and compiled under purview. Results: In India, licensing these products is under the act provisions and the rules known as the Drugs and Cosmetics Act, whereas globally regulatory provisions follow the guidelines of developed countries like the U.S. Food and Drug Administration, European Medicines Agency, the Therapeutic Goods Act, or the World Health Organization’s regulations for herbal products. Conclusions: The present communication highlights the provisions of regulatory and/or licensing requirements related to corporates, product composition, specifications, quality parameters, manufacturing methodology, stability, safety, preclinical studies, clinical studies, etc. for herbal products and the respective guidelines at one site. Highlights: Ultimately, all regulatory agencies across the world highlight majorly the safety and thereafter the efficacy for any products under the category.
    Materialart: Online-Ressource
    ISSN: 1060-3271 , 1944-7922
    Sprache: Englisch
    Verlag: Oxford University Press (OUP)
    Publikationsdatum: 2019
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 6
    Online-Ressource
    Online-Ressource
    SAGE Publications ; 2011
    In:  Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector Vol. 8, No. 4 ( 2011-10), p. 219-226
    In: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, SAGE Publications, Vol. 8, No. 4 ( 2011-10), p. 219-226
    Kurzfassung: Pharmaceutical market in Japan is the largest in Asia by value. ICH comprises three developed regions namely USA, Europe, and Japan. Though majority of regulations are harmonized, Japan’s regulations are yet less explored compared to USA and Europe perhaps due to language barriers. Sharing of vital technological information to the drug product manufacturer remains a cause of concern to the manufacturers of ingredients and packaging components. Master files are voluntary vehicles for conveying product and manufacturing information from suppliers and contractors directly to regulators to support new drug and biologic product review, and may have open and closed sections. The latter contains confidential information for regulator’s reference. Japan has master file systems that accommodate a broader range of drug and components like packaging materials. Japan added a master file system similar to the US model by updating its regulatory process under the 2005 Pharmaceutical Affairs Law. The accreditation of manufacturing facility is one of the very unique features of master file system as unlike US and Europe, for Japan facility approval process starts well before the submission of the actual drug master file. The stability requirements involve more sample analysis compared to the other international regulatory compliance requirements. Point has to be noted that data equivalent to module 2 of common technical document and application form are required to be translated in Japanese language. However, the quality section (module 3) can be submitted in English language. Understanding of master file system is important for companies entering into the Japanese market. The master file system of Japan is discussed in this article.
    Materialart: Online-Ressource
    ISSN: 1741-1343 , 1741-7090
    Sprache: Englisch
    Verlag: SAGE Publications
    Publikationsdatum: 2011
    ZDB Id: 2174701-5
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 7
    In: International Journal of Environmental Research and Public Health, MDPI AG, Vol. 19, No. 19 ( 2022-09-24), p. 12098-
    Kurzfassung: The 2019 worldwide sales of Orphan Drugs were estimated at $136 billion USD, which constituted 16% of the global pharmaceutical prescription market and is expected to grow by 12% in the next 5 years. A better understanding of Orphan Drug pricing may contribute to on-going discussions on Orphan Drug Act (ODA) corrections in US or modifications of price setting mechanisms in EU. The objective of the study was comparison and analysis of the prices of Orphan Drugs in US and EU. All drugs with Orphan Drug status were compared in the US and EU. For the US prices, the US Department of Veterans Affairs (VA) was sourced. The EU List Prices came from six EU countries: Denmark, France, Germany, Greece, Poland, Spain. We found US prices to be higher than the six selected EU countries. The average Price Ratio was 1.64. The prices across EU countries were more homogeneous, while the number of the reimbursed and therefore available to patient medicines varied and was correlated with GDP per capita r = 0.87. Considered implementation of the External Reference Price system in US may generate significant savings in the US but may result in upward pressure on pricing of Orphan Drugs in EU. Centralization of the Orphan Drugs pricing negotiations in EU may prevent such development and offer a win-win opportunity for all involved parties.
    Materialart: Online-Ressource
    ISSN: 1660-4601
    Sprache: Englisch
    Verlag: MDPI AG
    Publikationsdatum: 2022
    ZDB Id: 2175195-X
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 8
    Online-Ressource
    Online-Ressource
    SAGE Publications ; 2017
    In:  International Journal of Toxicology Vol. 36, No. 4 ( 2017-07), p. 293-302
    In: International Journal of Toxicology, SAGE Publications, Vol. 36, No. 4 ( 2017-07), p. 293-302
    Kurzfassung: Clinical pathology testing is routinely performed in target animal safety studies in order to identify potential toxicity associated with administration of an investigational veterinary pharmaceutical product. Regulatory and other testing guidelines that address such studies provide recommendations for clinical pathology testing but occasionally contain outdated analytes and do not take into account interspecies physiologic differences that affect the practical selection of appropriate clinical pathology tests. Additionally, strong emphasis is often placed on statistical analysis and use of reference intervals for interpretation of test article–related clinical pathology changes, with limited attention given to the critical scientific review of clinically, toxicologically, or biologically relevant changes. The purpose of this communication from the Regulatory Affairs Committee of the American Society for Veterinary Clinical Pathology is to provide current recommendations for clinical pathology testing and data interpretation in target animal safety studies and thereby enhance the value of clinical pathology testing in these studies.
    Materialart: Online-Ressource
    ISSN: 1091-5818 , 1092-874X
    Sprache: Englisch
    Verlag: SAGE Publications
    Publikationsdatum: 2017
    ZDB Id: 1500682-7
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 9
    Online-Ressource
    Online-Ressource
    International Journal for Modern Trends in Science and Technology (IJMTST) ; 2020
    In:  International Journal for Modern Trends in Science and Technology Vol. 6, No. 11 ( 2020-11-30), p. 143-146
    In: International Journal for Modern Trends in Science and Technology, International Journal for Modern Trends in Science and Technology (IJMTST), Vol. 6, No. 11 ( 2020-11-30), p. 143-146
    Kurzfassung: The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the COVID vaccines market is attributed majorly to the rising number of people infected with COVID-19 and increasing funding for vaccine development. On the other hand, the global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of the COVID drugs market is primarily attributed to use of repurposed drugs for compassionate use, and the emergence of alternative therapies such as convalescent plasma therapy which were earlier used for treating epidemic diseases such as SARS, MERS, and H1N1. Moreover, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies are fueling the market growth. Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. The Herculean effort means that a fast-tracked vaccine could come to market anywhere from the end of 2020 to the middle of 2021. To date, just two coronavirus vaccine has been approved. Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August. Experts have raised considerable concern about the vaccine’s safety and efficacy given it has not yet entered Phase 3 clinical trials. A second vaccine in Russia, EpiVacCorona, has also been granted regulatory approval, also without entering Phase 3 clinical trials. Operation Warp Speed (OWS) is a collaboration of several US federal government departments including Health and Human Services and its subagencies, Agriculture, Energy and Veterans Affairs and the private sector. OWS has selected three vaccine candidates to fund for Phase 3 trials: Moderna’s mRNA-1273, University of Oxford and AstraZeneca’s AZD1222, and Pfizer and BioNTech's BNT162. Within OWS, the US National Institutes of Health (NIH) has partnered with more than 18 biopharmaceutical companies to accelerate development of drug and vaccine candidates for COVID-19 (ACTIV). The COVID-19 Prevention Trials Network (COVPN) has also been established, which combines clinical trial networks funded by the National Institute of Allergy and Infectious Diseases (NIAID): the HIV Vaccine Trials Network (HVTN), HIV Prevention Trials Network (HPTN), Infectious Diseases Clinical Research Consortium (IDCRC), and the AIDS Clinical Trials Group.
    Materialart: Online-Ressource
    ISSN: 2455-3778
    URL: Issue
    Sprache: Englisch
    Verlag: International Journal for Modern Trends in Science and Technology (IJMTST)
    Publikationsdatum: 2020
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 10
    Online-Ressource
    Online-Ressource
    Cambridge University Press (CUP) ; 2017
    In:  International Journal of Technology Assessment in Health Care Vol. 33, No. S1 ( 2017), p. 129-129
    In: International Journal of Technology Assessment in Health Care, Cambridge University Press (CUP), Vol. 33, No. S1 ( 2017), p. 129-129
    Kurzfassung: The infectious Diseases Institute (IDI) is a research institute at the College of Health Sciences, Makerere University. Over the years, the number of research studies has greatly increased with an average of fifty active studies per year. Because of the voluminous study activities, investigators were faced with inadvertences of ethical approval deadlines (1). In 2015, a centralized electronic Regulatory Affairs Information System (RAIS) was developed and piloted to track the regulatory process of the entire research projects. RAIS is a web-based system, developed using a Net framework and runs on any operating system using a web browser such as “Google Chrome” and “Mozilla Firefox”. METHODS: A signed approval letter from an accredited Research Ethics Committee, National Drug Authority and Uganda National Council of Science and Technology, the reviewed protocol, consent forms and data collection tools are uploaded electronically into the RAIS with study staff contact information, CVs and Good Clinical Practice (GCP) certificates. RAIS sends automatic “no reply” emails to the investigators and research administration notifying for the need of annual renewal 56, 28 and 14 days before the expiry date of the approvals. The investigator or designated person prepares the application package which is then forwarded to the Research Regulatory Officer for review and submission to the regulatory authority. RESULTS: From January 2015 to November 2016, fourty-three ongoing studies were uploaded to the RAIS of which eleven were clinical trials, twenty-one observational studies, seven diagnostic and four implementation studies. Studies that obtained their annual approvals before the expiry date was 90.7 percent, compared to 29 percent that had reported early submission for annual renewal between January 2013 and December 2014. RAIS has enabled continuity of study activities with timely annual renewed approvals, supported the tracking of staff GCP certificates and populated timely notifications to investigators, resulting in submission of annual application packages on time. CONCLUSIONS: RAIS has strengthened ethical regulatory compliance and provided an effective platform for tracking regulatory processes, thus enabled continuity of study activities with timely annual renewal approvals and greatly supported the tracking of staff GCP certificates.
    Materialart: Online-Ressource
    ISSN: 0266-4623 , 1471-6348
    Sprache: Englisch
    Verlag: Cambridge University Press (CUP)
    Publikationsdatum: 2017
    ZDB Id: 2020486-3
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...